These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36740813)

  • 1. Efficacy of aprepitant as a prophylactic medication in adults with cyclic vomiting syndrome.
    Patel M; Partovi O; Mooers H; Kovacic K; Garacchi Z; Venkatesan T
    Neurogastroenterol Motil; 2023 Apr; 35(4):e14530. PubMed ID: 36740813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome.
    Cristofori F; Thapar N; Saliakellis E; Kumaraguru N; Elawad M; Kiparissi F; Köglmeier J; Andrews P; Lindley KJ; Borrelli O
    Aliment Pharmacol Ther; 2014 Aug; 40(3):309-17. PubMed ID: 24898244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly effective use of aprepitant in an adolescent girl with severe cyclic vomiting syndrome.
    Nivatsi M; Aslanidou I; Mantadakis E
    BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33664041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
    Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors.
    Duggin K; Tickle K; Norman G; Yang J; Wang C; Cross SJ; Gajjar A; Mandrell B
    J Pediatr Oncol Nurs; 2014; 31(5):277-83. PubMed ID: 24972782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
    Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
    Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association.
    Venkatesan T; Levinthal DJ; Tarbell SE; Jaradeh SS; Hasler WL; Issenman RM; Adams KA; Sarosiek I; Stave CD; Sharaf RN; Sultan S; Li BUK
    Neurogastroenterol Motil; 2019 Jun; 31 Suppl 2(Suppl 2):e13604. PubMed ID: 31241819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroparesis-associated refractory nausea treated with aprepitant.
    Fahler J; Wall GC; Leman BI
    Ann Pharmacother; 2012 Dec; 46(12):e38. PubMed ID: 23191934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of aprepitant and fosaprepitant in pediatric patients.
    Saito Y; Kumamoto T; Arima T; Shirakawa N; Ishimaru S; Sonoda T; Nakajima M; Sugiyama M; Arakawa A; Hashimoto H; Makino Y; Ogawa C; Yamaguchi M
    Pediatr Int; 2019 Mar; 61(3):235-239. PubMed ID: 30615239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
    Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
    Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
    Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders.
    Pasricha PJ; Yates KP; Sarosiek I; McCallum RW; Abell TL; Koch KL; Nguyen LAB; Snape WJ; Hasler WL; Clarke JO; Dhalla S; Stein EM; Lee LA; Miriel LA; Van Natta ML; Grover M; Farrugia G; Tonascia J; Hamilton FA; Parkman HP;
    Gastroenterology; 2018 Jan; 154(1):65-76.e11. PubMed ID: 29111115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis.
    Wu CE; Liaw CC
    Support Care Cancer; 2012 Oct; 20(10):2357-61. PubMed ID: 22187110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective review of patients treated for cyclic vomiting syndrome with topiramate.
    Mooers H; Srivastava S; Garacci E; Venkatesan T
    Aliment Pharmacol Ther; 2021 Jul; 54(2):153-159. PubMed ID: 34114666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
    Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
    Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Daily Administration of Aprepitant for the Management of Intractable Nausea and Vomiting in Children With Life-Limiting Conditions: A Case Series.
    Patel B; Downie J; Bayliss J; Stephenson A; Bluebond-Langner M
    J Pain Symptom Manage; 2021 Sep; 62(3):e225-e231. PubMed ID: 33587995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emesis control by aprepitant in children and adolescents with chemotherapy.
    Bauters TG; Verlooy J; Robays H; Benoit Y; Laureys G
    Int J Clin Pharm; 2013 Dec; 35(6):1021-4. PubMed ID: 24002338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.